Getting Ready for the Bounce: Cytokinetics Inc (CYTK) Stock

UBS raised the price target for the Cytokinetics Inc (NASDAQ:CYTK) stock from “a Buy” to “a Neutral”. The rating was released on January 24, 2024, according to finviz. We previously noted in another research note published on January 05, 2024 by Morgan Stanley that downgraded the stock from an Overweight to an Equal-weight with a price target of $90 for CYTK stock. The research report from Goldman has initiated the stock to Buy, with a price target set at $50. The stock was initiated by B. Riley Securities, who disclosed in a research note on November 07, 2023, to Buy and set the price objective to $66. In their research brief published August 15, 2023, SVB Securities analysts initiated the Cytokinetics Inc stock to Outperform with a price target of $58.

Historical Earnings Surprises and Revenue Forecasts

Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$1.38 during the last quarter as opposed to a consensus estimate of -$0.97, which indicates the company missed its estimate by -$0.41, which implies that the company surprised the market by -42.30%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2024) is -$1.14. This is an average of 14 analysts’ earnings, where the high earnings per share estimate is -$0.89 and the low earnings per share estimate is -$1.36.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The latest trade, Performances and Moving Averages give us the following Picture

The firm’s stock price fluctuated 6.18% within the last five trades and -4.08% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 134.32% in the last 6 months and -15.98% was subtracted to its value over the previous 3 months. CYTK stock is trading at a margin of 4.27%, -6.06% and 47.37% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

As of the close of trading, CYTK deals in the Healthcare domain. The stock is trading -36.41 percent below its 52-week high and 169.86 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 25.3. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Cytokinetics Inc’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at -6589.71 percent and the profit margin is -6988.63 percent, and the company has reported a gross margin of -82.78 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $7.22 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 959.01 that mirrors the cost to be found for sales by the market.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 3.66 percent of Cytokinetics Inc shares are owned by insiders, and 109.87 percent are held by financial institutions. Malik Fady Ibraham, the EVP Research & Development at Cytokinetics Inc (CYTK) has sold 32,604 shares of firm on Mar 05 ’24 at a price of $67.56 against the total amount of $2.2 million. In another inside trade, HENDERSON JOHN T, Director of Cytokinetics Inc (NASDAQ:CYTK) sold 5,000 shares of the firm on Feb 14 ’24 for a total worth of $0.38 million at a price of $76.48. An inside trade which took place on Feb 13 ’24, President & CEO of Cytokinetics Inc Blum Robert I sold 12,500 shares of firm against total price of $0.96 million at the cost of $76.85 per share.

Most Popular

Related Posts